NormOxys Appoints David Clark, MD, as Company's First Chief Medical Officer
Former Pfizer Executive Brings Extensive Clinical Experience
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, announced today the appointment of David Clark, MD, as its first Chief Medical Officer. Dr. Clark will manage NormOxys' clinical affairs, including the development of its lead product candidate, OXY111A, which is expected to enter clinical trials in the first quarter of 2010.
Dr. Clark has more than 12 years of global pharmaceutical drug development experience, spanning preclinical to Phase IV programs, including NDA submissions. These programs have covered six different therapeutic areas and included extensive interactions with regulatory authorities in the United States, European Union, and Japan.
"David's demonstrated record of driving products through clinical development to support regulatory and commercial success will be instrumental as we advance our pipeline of products," said Martin Tolar, MD, PhD, President and Chief Executive Officer of NormOxys. "As we prepare to submit INDs with the FDA for our lead candidate and initiate clinical trials in the first quarter of next year, David's experience and expertise will be invaluable to NormOxys."
Prior to joining NormOxys, Dr. Clark led clinical teams while working in the Clinical Development division at Pfizer for close to a decade. Before Pfizer, Dr. Clark was employed by SmithKline Beecham and GlaxoSmithKline in their Clinical Pharmacology and Translational Medicine groups.
Dr. Clark earned his MD degree from the University of Edinburgh Medical School and he completed his postgraduate medical training in internal medicine in Scotland and New Zealand. He is a Member of the Royal College of Physicians and has published extensively in the respiratory clinical pharmacology field.
"I am delighted to be joining NormOxys at such an exciting time of growth," said Dr. Clark, Chief Medical Officer, NormOxys. "I am particularly excited about the potential of the company's science and the potential for a new class of drugs, oxyrens, to make a significant difference in treating a wide range of high morbidity and high mortality diseases through enhanced, regulated oxygen delivery to diseased tissues."
NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body's ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues, such as cancer, cardiovascular diseases, anemia, Alzheimer's' disease, stroke and diabetic retinopathy. The company is based in Boston, MA and was founded by Prof. Claude Nicolau, PhD, and Nobel Laureate Prof. Jean-Marie Lehn, PhD, based on their groundbreaking investigations in chemistry and cellular biophysics. To learn more about NormOxys, please visit the Company's website at www.normoxys.com